Skip to content

Study · Not a test of the peptide alone · 2004

3 results

[Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma].

Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ

Zhonghua zhong liu za zhi [Chinese journal of oncology]1 May 2004Cited by 11 (Europe PMC)

PMID15312371 (opens in a new tab)PepBankPUB-15312371
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, the 1-year recurrence rate did not differ significantly between hepatectomy plus TACE and thymosin alpha‑1 (83.3%), hepatectomy plus TACE (87.0%) and hepatectomy only (87.5%).

    In plain wordsIn people with liver cancer after surgery, one-year cancer return rates were similar with TACE plus thymosin alpha‑1, TACE alone, or surgery alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant change1-year recurrence rate
    Study

    n = 57

    Comparator
    Hepatectomy plus TACE (group B); hepatectomy only (group C)
    Outcome group
    Tumor growth · Cancer

    Measurements

    1-year recurrence rate
    83.3%
    group A
    1-year recurrence rate
    87%
    group B
    1-year recurrence rate
    87.5%
    group C

    Source sentences

    Summary
    For group A, B and C, the 1 year recurrence rate was 83.3%, 87.0% and 87.5% (P = 0.926), respectively.
    1 context sentence
    Summary · context
    From Jan 2000 to Dec 2002, 57 patients with HCC were randomly divided into three groups: group A (n = 18) received hepatectomy plus postoperative TACE and T(alpha1), group B (n = 23) received hepatectomy plus postoperative TACE and group C (n = 16) received hepatectomy only.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, time to tumor recurrence was longer with postoperative TACE plus thymosin alpha‑1 (7.0 months) than with TACE (5.0 months) or hepatectomy only (4.0 months).

    In plain wordsIn people with liver cancer after surgery, cancer took longer to return with TACE plus thymosin alpha‑1 than with TACE or surgery alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTime to tumor recurrence
    Study

    n = 57

    Comparator
    Hepatectomy plus TACE (group B); hepatectomy only (group C)
    Outcome group
    Tumor growth · Cancer

    Measurements

    Time to recurrence
    7 months
    group A
    Time to recurrence
    5 months
    group B
    Time to recurrence
    4 months
    group C

    Source sentences

    Summary
    The time to tumor recurrence was 7.0, 5.0 and 4.0 months (P = 0.039), respectively.
    1 context sentence
    Summary · context
    From Jan 2000 to Dec 2002, 57 patients with HCC were randomly divided into three groups: group A (n = 18) received hepatectomy plus postoperative TACE and T(alpha1), group B (n = 23) received hepatectomy plus postoperative TACE and group C (n = 16) received hepatectomy only.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, median survival was longer with postoperative TACE plus thymosin alpha‑1 (10.0 months) than with TACE (7.0 months) or hepatectomy only (8.0 months).

    In plain wordsIn people with liver cancer after surgery, median survival was longer with TACE plus thymosin alpha‑1 than with TACE alone or surgery alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian survival
    Study

    n = 57

    Comparator
    Hepatectomy plus TACE (group B); hepatectomy only (group C)
    Outcome group
    Mortality · Cancer

    Measurements

    Median survival
    10 months
    group A
    Median survival
    7 months
    group B
    Median survival
    8 months
    group C

    Source sentences

    Summary
    The median survival was 10.0, 7.0 and 8.0 months (P = 0.002), respectively.
    1 context sentence
    Summary · context
    From Jan 2000 to Dec 2002, 57 patients with HCC were randomly divided into three groups: group A (n = 18) received hepatectomy plus postoperative TACE and T(alpha1), group B (n = 23) received hepatectomy plus postoperative TACE and group C (n = 16) received hepatectomy only.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.